Shanghai, China – 4 January, 2015 – Shanghai MicroPort Medical (Group) Co ("MicroPort") recently gained approval from China Food and Drug Administration ("CFDA") to add 24 specifications to Firehawk® Rapamycin Target Eluting Coronary Stent ("Firehawk®").
Firehawk® is MicroPort's third-generation drug eluting stent ("DES"), following Firebird™ Rapamycin-Eluting Coronary Stent and Firebird2™ Rapamycin-Eluting Coronary CoCr Stent, to treat coronary artery stenosis or occlusion diseases. As the world's first and only target eluting stent ("TES"), Firehawk® combines the advantages of DES and bare metal stents. Its applied targeted eluting technology allows it to achieve the same clinical efficacy as traditional DES with much lower drug dosage, and therefore greatly improving the safety of Firehawk® while maintaining its excellent efficacy.
Firehawk® was first approved for market launch by CFDA on January 23, 2014. Up to date, it has entered into 60 hospitals in 17 provinces/cities of China. With more specifications, Firehawk® will offer patients and surgeons more options to better serve their needs.